Clinic menus increasingly sell a trio of 'intimacy peptides' as if they were variations on one theme. They are three different mechanisms with three very different evidence stories: one has an FDA-approved sibling, one is a genuinely exciting research molecule with no products worth buying, and one is a beloved hormone whose supplement hype collapsed under trial data.
The scorecard
| PT-141 (bremelanotide) | Kisspeptin | Oxytocin | |
|---|---|---|---|
| Mechanism | Melanocortin receptors, central desire pathways | Master regulator of the reproductive hormone axis (GnRH trigger) | Bonding and social neuropeptide |
| Best evidence | FDA approval as Vyleesi for HSDD in premenopausal women | Elegant small trials (Imperial College and others) improving sexual-brain responses in HSDD | Large trials of intranasal oxytocin mostly null for behavior change |
| Product reality | Approved autoinjector plus gray-market vials | Research settings only; gray-market vials are ahead of any validated use | Compounded nasal sprays and troches, sold on collapsed evidence |
| Honest status | The proven-mechanism one, with blood-pressure cautions | The most scientifically interesting, least buyable | The most sold, least supported |
What the comparison teaches
PT-141 is the only member with a regulator-validated effect on desire, and it carries real cardiovascular cautions covered in our full guide. Kisspeptin is the molecule to watch: its physiology (upstream switch of the entire reproductive axis) is spectacular, its early HSDD trials are genuinely promising, and precisely none of that validates the research-chemical vials sold today. Oxytocin is the cautionary tale: decades of hype, a wave of intranasal trials, and a mostly null result for the behavioral claims, which the compounding market has simply declined to notice. Three menus items, one actual product, one future, one museum piece.
Frequently asked questions
Which works best, PT-141, kisspeptin, or oxytocin?
PT-141 is the only one with an approved, trial-validated effect on sexual desire (as Vyleesi, in premenopausal women with HSDD). Kisspeptin shows promising early trial signals but has no validated product; intranasal oxytocin's behavioral claims largely failed in controlled trials.
What does kisspeptin do?
It is the upstream trigger of the reproductive hormone axis, and small controlled studies have shown intranasal or IV kisspeptin modulating sexual-processing brain responses in people with low desire. Fascinating science; the gray-market vials borrowing it are years ahead of any validated use.
Does oxytocin nasal spray work for intimacy?
The large controlled-trial record is mostly null for behavioral and relationship outcomes, which is why mainstream interest cooled. Compounded 'love hormone' products sell the early hype, not the later data.